May 13th 2024
While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.
Referring Patients for Telephone Counseling to Promote Colorectal Cancer Screening
In this pilot study, primary care providers refer patients to a telephone counselor who provides education about colorectal cancer screening and performs motivational interviewing as needed to promote screening.
Read More
Segment 7 - The Payer's Role and Future Trends
September 12th 2013Panelists all agree that there needs to be evidence and guidelines for both payers and providers. There are not enough resources to try every drug on every patient. Although it will be costly, there needs to be evidence on putting these drugs together as combinations.
Read More
Segment 6 - Personalized Medicine
September 12th 2013Dr Crawford said that in order to pick the appropriate treatment for a diagnosed patient with prostate cancer, it is important to think outside of the box. The National Comprehensive Cancer Network (NCCN) and the American Urological Association (AUA) offer castration-resistant prostate cancer (CRPC) guidelines that serve as the best guideline for payers.
Read More
It is an exciting time for prostate cancer due to the growth in new treatments. Dr George said that it is, in fact, both exciting and daunting to have all of these new agents being developed. Currently, there is a shortage in data for practitioners in using the new agents in sequence or combination.
Read More
Segment 4 - Advances and Challenges in Prostate Cancer
September 12th 2013In this segment of the panel discussion, Dr Fendrick asks the panelists if there is now a sense of optimism in reducing the mortality and quality gaps in prostate cancer treatment due to targeted screening and new molecular diagnostics, and immunotherapies.
Read More
Cancer Patient Stuck with Higher Bills as Obama Pre-existing Condition Plan Runs Low on Cash
September 10th 2013Coping with advanced cancer, Bev Veals was in the hospital for chemo this summer when she got a call that her health plan was shutting down. Then, the substitute insurance she was offered wanted her to pay up to $3,125, on top of premiums.
Read More
Cancer, Managed Care Experts to Lead Talks on How Consumers Will Create Change
September 9th 2013Healthcare reform will bring new payment models and new power for consumers, and cancer care delivery will not be immune. With that in mind, The American Journal of Managed Care will bring together experts from the front lines to Baltimore, Maryland, November 14-15 for a conference to share how the goals of better care, savings and fair compensation can be achieved, even in the world of oncology.
Read More
Sequester Forcing Chemo Treatments into Hospital Settings, Costing Taxpayers More in the End
August 21st 2013The federal sequester trims Medicare payments for cancer patients receiving chemotherapy in doctors' offices in an effort to save the government money. Instead, it will end up costing more in the long run, according to the president of the American Society of Clinical Oncology (ASCO).
Read More
Panel Discusses Costly New Oncology Drugs; Study Address Cancer Drug Shortages
August 21st 2013Although researchers have made powerful new targeted treatment options available to oncologists who treat breast cancer patients, options such as pertuzumab are associated with high costs which raises questions about access as payers assess the value of treatment.
Read More
Michael Kolodziej Says Provider-Payer Connections Key in Quality, Cost-Effective Cancer Care
August 15th 2013In order to deliver quality and cost-effective cancer care, Michael Kolodziej, MD, Aetna's national medical director for oncology strategies, says that providers need to get better connected with payers.
Read More